Covid 19 Research using Clinical Trials (Home Page)
Report for D000857: Olfaction Disorders NIH
(Synonyms: Olf, Olfaction Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (11)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug989 | Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki | 0.53 |
| drug1547 | corticosteroid nasal irrigation Wiki | 0.38 |
| drug872 | Nasal Irrigation Wiki | 0.38 |
| drug1618 | olfactory and gustatory tests Wiki | 0.38 |
| drug1011 | Physiological serum Wiki | 0.38 |
| drug934 | Olfactory retraining Wiki | 0.38 |
| drug539 | General Public cohort Wiki | 0.38 |
| drug222 | Budesonide Nasal Wiki | 0.38 |
| drug856 | NHANES smell and taste tests Wiki | 0.38 |
| drug1656 | smell household Items Wiki | 0.38 |
| drug209 | Blood samples (collection of 5 mL of blood in a dry tube) Wiki | 0.38 |
Correlated MeSH Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004408 | Dysgeusia NIH | 0.53 |
| D000370 | Ageusia NIH | 0.38 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D007239 | Infection NIH | 0.05 |
| D014777 | Virus Diseases NIH | 0.05 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000458 | Anosmia HPO | 1.00 |
| HP:0000224 | Decreased taste sensation HPO | 0.38 |
There are 7 clinical trials
Clinical Trials
1 Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.
NCT04354857 COVID-19 Other: olfactory and gustatory tests MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: Positive/negative according to RT-PCR assay
Measure: SARS-CoV-2 infection status Time: Day 0
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 0
Secondary Outcomes
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Day 0
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Six months
Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Day 0
Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Six months
Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Day 0
Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Six months
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 7
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 14
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 30
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 60
Description: % patients hospitalized
Measure: Severity of infection according to hospitalization rate Time: End of study (six months)
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Six months
2 A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
Primary Outcomes
Description: Positive/negative according to RT-PCR assay
Measure: SARS-CoV-2 infection status Time: Day 0Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 0Secondary Outcomes
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Day 0Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Six monthsDescription: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Day 0Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Six monthsDescription: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Day 0Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Six monthsDescription: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 7Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 14Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 30Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 60Description: % patients hospitalized
Measure: Severity of infection according to hospitalization rate Time: End of study (six months)Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Six monthsThe initial symptoms described in the first cases of COVID-19 were mainly fever and respiratory signs. Recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life. Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. Because of the possible development of severe forms of the SARS-Cov-2 infection, the French Society of Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. However, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of COVID-19 without risk of dissemination. In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. However, this drug does not have marketing authorisation in France for this indication.
NCT04361474 Budesonide Olfaction Disorders SARS-CoV-2 Anosmia Drug: Budesonide Nasal Other: Physiological serum MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment
Measure: Patient with more than 2 points on the ODORATEST Time: 30 days
3 Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial
Primary Outcomes
Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment
Measure: Patient with more than 2 points on the ODORATEST Time: 30 daysThe study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.
NCT04374474 Olfactory Disorder Other: Olfactory retraining Drug: corticosteroid nasal irrigation Other: smell household Items Other: Nasal Irrigation MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 3 months Time: 3 months
Description: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 3 months Time: 3 months
Description: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 6 months Time: 6 months
Description: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 6 months Time: 6 months
Secondary Outcomes
Description: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 3 months Time: 3 months
Description: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 3 months Time: 3 months
Description: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 6 months Time: 6 months
Description: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 6 months Time: 6 months
Description: Adherence comparison between participants post-CoVID 19 and patients post other viral infections.
Measure: Adherence to the Study Protocol Time: 6 months
Description: Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.
Measure: Recovery Time: 6 months
4 FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste
Primary Outcomes
Description: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 3 months Time: 3 monthsDescription: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 3 months Time: 3 monthsDescription: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 6 months Time: 6 monthsDescription: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 6 months Time: 6 monthsSecondary Outcomes
Description: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 3 months Time: 3 monthsDescription: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 3 months Time: 3 monthsDescription: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 6 months Time: 6 monthsDescription: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 6 months Time: 6 monthsDescription: Adherence comparison between participants post-CoVID 19 and patients post other viral infections.
Measure: Adherence to the Study Protocol Time: 6 monthsDescription: Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.
Measure: Recovery Time: 6 monthsThe FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.
NCT04377815 COVID-19 Anosmia Other: General Public cohort MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: percentage of people who report loss/reduced sense of smell or taste
Measure: Percentage of people reporting changes in smell/taste Time: 4 weeks
Description: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.
Measure: mortality rate Time: through study completion, an average of 1 year
Secondary Outcomes
Description: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with change in smell/taste before other symptoms Time: 4 weeks
Description: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.
Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change Time: 4 weeks
Description: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with persistent changes in smell and/or taste Time: 12 weeks
Description: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19
Measure: Percentage of hospitalisation Time: 12 weeks
Description: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19
Measure: co-morbidities association Time: through study completion, an average of 1 year
Description: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.
Measure: prevalence of changes in smell/taste Time: through study completion, an average of 1 year
Description: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.
Measure: clinical outcomes Time: through study completion, an average of 1 year
5 Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Case-Control Study
Primary Outcomes
Description: percentage of people who report loss/reduced sense of smell or taste
Measure: Percentage of people reporting changes in smell/taste Time: 4 weeksDescription: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.
Measure: mortality rate Time: through study completion, an average of 1 yearSecondary Outcomes
Description: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with change in smell/taste before other symptoms Time: 4 weeksDescription: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.
Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change Time: 4 weeksDescription: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with persistent changes in smell and/or taste Time: 12 weeksDescription: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19
Measure: Percentage of hospitalisation Time: 12 weeksDescription: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19
Measure: co-morbidities association Time: through study completion, an average of 1 yearDescription: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.
Measure: prevalence of changes in smell/taste Time: through study completion, an average of 1 yearDescription: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.
Measure: clinical outcomes Time: through study completion, an average of 1 yearThe Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The case-control study is described here (the cross-sectional study is described in a separate ClinicalTrials.gov record).
NCT04384042 SARS-CoV Infection COVID-19 Anosmia Dysgeusia Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Dysgeusia
HPO:Anosmia
Primary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection
Description: The relationship between case & control status and each exposure variable will be estimated by odds ratios and their 95% confidence intervals using conditional logistic regression models.
Measure: Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection
Secondary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19/within the past 2 weeks of answering the questionnaire (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection
Description: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: Baseline
Description: PPV reflects the probability that the presence of olfactory and taste disturbances will have a positive diagnosis of COVID-19. This is derived from dividing the number of patients with olfactory & taste disturbances with COVID-19 infection over the total number of patients with olfactory and taste disturbances, and multiplying by 100%
Measure: Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection Time: Baseline
Description: NPV reflects the probability that the absence of olfactory and taste disturbances will have a negative diagnosis of COVID-19. This is derived from dividing the number of patients without olfactory & taste disturbances and without COVID-19 infection over the total number of patients with no olfactory and taste disturbances, and multiplying by 100%
Measure: Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection Time: Baseline
Description: The percentage of true positives, i.e. the proportion of patients with olfactory and taste disorders with COVID-19 infection. This can be calculated by dividing the number of subjects with olfactory & taste disturbances who have COVID-19 infection with the number of patients with olfactory & taste disturbances, and multiplying by 100%
Measure: Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection Time: Baseline
Description: The percentage of true negatives, i.e. the proportion of patients without olfactory and taste disorders who do not have COVID-19 infection. This can be calculated by dividing the number of subjects without olfactory & taste disturbances who do not have COVID-19 infection with the number of patients without olfactory & taste disturbances, and multiplying by 100%
Measure: Specificity of olfactory and taste disturbances in predicting COVID-19 infection Time: Baseline
6 Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia
Primary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionDescription: The relationship between case & control status and each exposure variable will be estimated by odds ratios and their 95% confidence intervals using conditional logistic regression models.
Measure: Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionSecondary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19/within the past 2 weeks of answering the questionnaire (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: BaselineDescription: PPV reflects the probability that the presence of olfactory and taste disturbances will have a positive diagnosis of COVID-19. This is derived from dividing the number of patients with olfactory & taste disturbances with COVID-19 infection over the total number of patients with olfactory and taste disturbances, and multiplying by 100%
Measure: Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection Time: BaselineDescription: NPV reflects the probability that the absence of olfactory and taste disturbances will have a negative diagnosis of COVID-19. This is derived from dividing the number of patients without olfactory & taste disturbances and without COVID-19 infection over the total number of patients with no olfactory and taste disturbances, and multiplying by 100%
Measure: Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection Time: BaselineDescription: The percentage of true positives, i.e. the proportion of patients with olfactory and taste disorders with COVID-19 infection. This can be calculated by dividing the number of subjects with olfactory & taste disturbances who have COVID-19 infection with the number of patients with olfactory & taste disturbances, and multiplying by 100%
Measure: Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection Time: BaselineDescription: The percentage of true negatives, i.e. the proportion of patients without olfactory and taste disorders who do not have COVID-19 infection. This can be calculated by dividing the number of subjects without olfactory & taste disturbances who do not have COVID-19 infection with the number of patients without olfactory & taste disturbances, and multiplying by 100%
Measure: Specificity of olfactory and taste disturbances in predicting COVID-19 infection Time: BaselineCOVID-19 has adversely affected the healthcare system across the world. The world was not prepared for global outbreak of infectious diseases. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is enabling researchers worldwide to acquire a large amount of clinical data regarding coronavirus disease (COVID-19). The COVID-19 infection severely affects the respiratory system in the critical cases and results in mortalities. The affected people experience a dry cough, fever, breathing problems, diarrhea, muscle pain, and sore throat. Besides that, some of the evidence from Italy, South Korea, China, and Spain suggest that the COVID-19 cases also lose their senses of smell and taste resulting in alterations in those patients. The objective of this proposed study is to determine whether COVID-19 cases have Olfactory and gustatory dysfunctions as a hallmark indicator and can be used as diagnostic tools for the isolation of suspected people. Investigators are presenting a prospective proportional case-control study that is conducted to investigate the COVID-19 cases with anosmia and /or Ageusia in a university hospital in Riyadh, Saudi Arabia. The sample size of this case series would be 250 cases of suspected COVID-19 patients. The cases included in the study are analyzed prospectively to determine if the cases had a history of anosmia and /or Ageusia, and then tested for the alteration of these senses through a panel of standardized odors/taste strips. That is looked at statistically allowing us to confirm the proposed effectiveness of these tests as a diagnostic tool.
NCT04388618 Anosmia Ageusia Covid19 Corona Virus Infection Other: NHANES smell and taste tests MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Ageusia Virus Diseases
HPO:Anosmia Decreased taste sensation
Primary Outcomes
Description: to how extent alteration of smell and taste senses is related to covid19 status
Measure: correlation of anosmia and ageusia to covid19 positive patients Time: from 1/06/2020 to 31/12/2020
Secondary Outcomes
Description: to determine the range of sense affection ranging from total loss to mild form
Measure: objective assessment of severity of smell and taste senses alterations in covid19 patients Time: from 1/06/2020 to 31/12/2020
7 Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Cross-Sectional Study
Primary Outcomes
Description: to how extent alteration of smell and taste senses is related to covid19 status
Measure: correlation of anosmia and ageusia to covid19 positive patients Time: from 1/06/2020 to 31/12/2020Secondary Outcomes
Description: to determine the range of sense affection ranging from total loss to mild form
Measure: objective assessment of severity of smell and taste senses alterations in covid19 patients Time: from 1/06/2020 to 31/12/2020The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The cross-sectional study is described here (the case-control study is described in a separate ClinicalTrials.gov record).
NCT04390165 SARS-CoV Infection COVID-19 Anosmia Dysgeusia Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Dysgeusia
HPO:Anosmia
Primary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infection
Description: Percentage of COVID-19 patients experiencing olfactory disturbances (anosmia or hyposmia)
Measure: Prevalence of olfactory disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infection
Description: Percentage of COVID-19 patients experiencing taste disturbances
Measure: Prevalence of taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infection
Secondary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19 (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: Within 2 weeks preceding the diagnosis of COVID-19 infection
Description: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: Prior to diagnosis of COVID-19 infection
Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste before their diagnosis of COVID-19 infection
Measure: Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection Time: Prior to 2 weeks preceding the diagnosis of COVID-19 infection (Baseline)
Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of diagnosis of COVID-19 infection
Measure: Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection Time: Within 2 weeks preceding the diagnosis of COVID-19 infection
Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of answering questionnaire survey
Measure: Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey Time: Up to 6 months
HPO Nodes
HP:0000458: Anosmia
Genes 67
PEX7 NSMF DNAI1 FEZF1 IL17RD PHYH DCC TAC3 WDR11 GNRH1 IL17RD CCDC141 SPRY4 ATP13A2 HESX1 PROK2 CHD7 ANK1 TACR3 SMCHD1 FGFR1 NSMF FEZF1 ANOS1 ANOS1 SHH CHD7 ADCY3 FLRT3 SOX10 FGF8 FGF17 SOX10 HESX1 CCDC141 SEMA3A SOX10 SOX10 WDR11 KISS1 OTX2 PROKR2 CHD7 PROKR2 SOX3 PROK2 FGFR1 SOX2 PEX7 SEMA3E SEMA3E SEMA3A PROKR2 KISS1R HS6ST1 SMCHD1 CHD7 FGFR1 FGF8 MFN2 ARSL PEX7 KISS1R ARNT2 PHYH SCN9A DUSP6 Protein Mutations 0
SNP 0
Primary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: Percentage of COVID-19 patients experiencing olfactory disturbances (anosmia or hyposmia)
Measure: Prevalence of olfactory disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: Percentage of COVID-19 patients experiencing taste disturbances
Measure: Prevalence of taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionSecondary Outcomes
Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19 (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: Prior to diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste before their diagnosis of COVID-19 infection
Measure: Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection Time: Prior to 2 weeks preceding the diagnosis of COVID-19 infection (Baseline)Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of diagnosis of COVID-19 infection
Measure: Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of answering questionnaire survey
Measure: Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey Time: Up to 6 months